These findings are of clinical relevance, as it has been suggested that patients with stage II CRC (i.e. lymph node metastasis negative) with CDX2 loss represent a particular high-risk group that may benefit from adjuvant therapies4. This evidence concerns the gene CDX2 and colorectal carcinoma.